December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:QNTM)

9.800 -0.700 (-6.67%)
Streaming Delayed Price Updated: 3:35 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about QNTM

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Appoints Dr. Jack Antel as Clinical Advisor for MS Program
Via Investor Brand Network
News headline image
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Results of Annual General and Special Meeting
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives Health Canada Product License for Qlarity
Via Investor Brand Network
News headline image
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Licensee Unbuzzd Wellness to Host Investor Webinar on Sept. 16
Via Investor Brand Network
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives BUY Rating, $45 Price Target from Kingswood Capital Partners
Via Investor Brand Network
News headline image
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
This was unpaid research with no consideration given 
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) Provides Corporate Update
Via Investor Brand Network
News headline image
Quantum BioPharma Announces Corporate Updates
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) to Seek Shareholder Approval for $600K Private Placement
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Signs CDMO Agreement for Oral Lucid-MS in Phase 2 MS Trial
Via Investor Brand Network
News headline image
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) PET Tracer Shows Potential for Monitoring Myelin Integrity in Multiple Sclerosis
Via Investor Brand Network
News headline image
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of
Unprecedented Quarter Shows Company’s Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational Beverage and Alcohol Metabolizer 
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Positive Phase 1 Safety Results for Lucid-MS
Via Investor Brand Network
News headline image
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Opposes Motion to Dismiss in $700 Million Market Manipulation Lawsuit
Via Investor Brand Network
News headline image
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Portfolio Company Unbuzzd Wellness Launches $5 Million Regulation D Offering
Via Investor Brand Network
Topics Initial Public Offering
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
This Offering Will Not Dilute Quantum BioPharma Shareholders 
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Makes Strategic Investment in GameStop Corp.
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise 
From Quantum BioPharma
Via GlobeNewswire
News headline image
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies,... 
Via Newsfile
Topics Initial Public Offering
News headline image
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 
From Quantum BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.